French Trial Tragedy: Dosing Continued After Volunteer Hospitalized
This article was originally published in SRA
Executive Summary
Data from the ill-fated Phase I dose-escalation study of Bial's FAAH inhibitor BIA 10-2474 reveal that the first serious adverse reaction occurred on the fifth day after the daily dose had been increased from 20 mg to 50 mg in the multiple-dosing stage of the trial1,2.
You may also be interested in...
Valneva Starts COVID-19 Vaccine Production In Scotland
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
Stakeholders To Have Say On Future Medicines Verification System In UK
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.
Sputnik V COVID-19 Vaccine Team Discusses EU Development Plan With EMA
The team behind Russia’s first COVID-19 vaccine has asked for scientific advice from EU drug regulators in view of a possible submission for marketing authorization.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: